Magnesium stearate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Magnesium stearate
DrugBank Accession Number
DB14077
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 591.244
Monoisotopic: 590.512452626
Chemical Formula
C36H70MgO4
Synonyms
  • Dibasic magnesium stearate
  • Magnesium distearate
  • Magnesium octadecanoate
  • Octadecanoic acid, magnesium salt
  • Stearic acid, magnesium salt
External IDs
  • SM 1000

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AtracuriumThe therapeutic efficacy of Atracurium can be increased when used in combination with Magnesium stearate.
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium stearate.
Botulinum toxin type AThe therapeutic efficacy of Botulinum toxin type A can be increased when used in combination with Magnesium stearate.
Botulinum toxin type BThe risk or severity of adverse effects can be increased when Magnesium stearate is combined with Botulinum toxin type B.
CapreomycinThe risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Magnesium stearate.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
DayclingTablet5 mg/1VaginalIstk32017-10-24Not applicableUS flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Medi Megaton 2080Magnesium stearate (0.005 g/100g) + Glycerin (0.002 g/100g) + Saw palmetto (0.01 g/100g) + Silicon dioxide (0.01 g/100g) + Titanium dioxide (0.001 g/100g) + Zinc oxide (0.0146 g/100g)PowderTopicalMbg Inc (Korea Institute of Science Development)2016-10-162017-10-16US flag
Medi Megaton 2080Magnesium stearate (0.005 g/100g) + Glycerin (0.002 g/100g) + Saw palmetto (0.01 g/100g) + Silicon dioxide (0.01 g/100g) + Titanium dioxide (0.001 g/100g) + Zinc oxide (0.0146 g/100g)PowderTopicalMbg Inc (Korea Institute of Science Development)2016-10-152017-10-15US flag
SAMTACIDMagnesium stearate (200 mg/5ml) + Aluminum hydroxide (200 mg/5ml) + Simethicone (30 mg/5ml)SuspensionSamco Farma2017-03-032024-02-14Indonesia flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
DayclingMagnesium stearate (5 mg/1)TabletVaginalIstk32017-10-24Not applicableUS flag
Medi Megaton 2080Magnesium stearate (0.005 g/100g) + Glycerin (0.002 g/100g) + Saw palmetto (0.01 g/100g) + Silicon dioxide (0.01 g/100g) + Titanium dioxide (0.001 g/100g) + Zinc oxide (0.0146 g/100g)PowderTopicalMbg Inc (Korea Institute of Science Development)2016-10-162017-10-16US flag
Medi Megaton 2080Magnesium stearate (0.005 g/100g) + Glycerin (0.002 g/100g) + Saw palmetto (0.01 g/100g) + Silicon dioxide (0.01 g/100g) + Titanium dioxide (0.001 g/100g) + Zinc oxide (0.0146 g/100g)PowderTopicalMbg Inc (Korea Institute of Science Development)2016-10-152017-10-15US flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
70097M6I30
CAS number
557-04-0
InChI Key
HQKMJHAJHXVSDF-UHFFFAOYSA-L
InChI
InChI=1S/2C18H36O2.Mg/c2*1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20;/h2*2-17H2,1H3,(H,19,20);/q;;+2/p-2
IUPAC Name
magnesium(2+) dioctadecanoate
SMILES
[Mg++].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O

References

General References
Not Available
KEGG Drug
D02189
ChemSpider
10704
RxNav
1310567
ChEBI
9254
ChEMBL
CHEMBL2106633
Wikipedia
Magnesium_stearate

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
4Active Not RecruitingTreatmentFemale Genitourinary Disease / Lower Urinary Tract Symptoms (LUTS) / Nocturia / Overactive Bladder Syndrome (OABS) / Quality of Life (QOL) / Stress Urinary Incontinence (SUI) / Urethral atrophy / Urinary Urge Incontinence (UUI) / Vagina Atrophy / Voiding Disorders1somestatusstop reasonjust information to hide
2Unknown StatusTreatmentCoronavirus Disease 2019 (COVID‑19)1somestatusstop reasonjust information to hide
1CompletedSupportive CareStable COPD Patients1somestatusstop reasonjust information to hide
1CompletedTreatmentAsthma1somestatusstop reasonjust information to hide
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletVaginal5 mg/1
TabletOral
PowderTopical
Suspension
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.13e-05 mg/mLALOGPS
logP10.89ALOGPS
logP7.15Chemaxon
logS-7.7ALOGPS
pKa (Strongest Acidic)4.95Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area40.13 Å2Chemaxon
Rotatable Bond Count32Chemaxon
Refractivity97.12 m3·mol-1Chemaxon
Polarizability38.18 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at June 17, 2018 16:58 / Updated at June 12, 2020 16:53